Coya Therapeutics reports improvement in inflammatory markers in Alzheimer's patients
- Coya Therapeutics announced positive results from a Phase 2 study of low-dose IL-2 in Alzheimer's patients.
- The study showed statistically significant reductions in proinflammatory markers and increases in anti-inflammatory cytokines with monthly dosing.
- Monthly low-dose IL-2 also led to improved cognitive scores and increased amyloid-beta clearance.
- Coya plans to publish and present these findings throughout 2025.
Read more
Alumis and ACELYRIN to merge creating a late-stage clinical biopharma company
- Alumis and ACELYRIN announced a merger to form a late-stage clinical biopharma company focused on immune-mediated diseases.
- The combined company will operate under the Alumis name, with a pro forma cash position of approximately $737 million.
- Alumis stockholders will own about 55% and ACELYRIN stockholders about 45% of the combined company.
- The merger is expected to close in the second quarter of 2025, pending stockholder approvals.
Read more
Neurocrine Biosciences reports fourth quarter and fiscal 2024 financial results
- INGREZZA achieved net product sales of $615 million in Q4 and $2.3 billion for the full year 2024, marking a 23% and 26% year-over-year growth, respectively.
- CRENESSITY, a treatment for congenital adrenal hyperplasia, was approved by the FDA in December 2024 and launched in the U.S., with initial sales of $2 million.
- Phase 3 programs for osavampator in major depressive disorder and NBI-568 in schizophrenia are set to begin in the first half of 2025.
- Neurocrine amended its collaboration with Takeda, granting exclusive rights to develop and commercialize osavampator globally, except in Japan.
Read more
